Tenpoint Therapeutics, Ltd. submitted a marketing authorisation application to the United Kingdom’s Medicines and Healthcare products Regulatory Agency on July 13, 2026, seeking approval of Yuvezzi, a once-daily combination eye drop for presbyopia in adults. The application was filed through the regulator’s International Recognition Procedure and relies partly on Yuvezzi’s January 2026 approval by the United States Food and Drug Administration, but the product is not yet authorised in the United Kingdom.
Yuvezzi, previously developed as Brimochol PF, combines carbachol 2.75% with brimonidine tartrate 0.1% in a preservative-free, single-dose formulation. The product has been commercially available across the United States since March 2026, making the United Kingdom application the next significant test of whether Tenpoint Therapeutics can convert a domestic regulatory success into an international ophthalmology franchise.
The filing also arrives as pharmaceutical treatment for presbyopia begins moving from an emerging United States category into a potentially competitive European market. Tenpoint Therapeutics said there are currently no prescription eye drops approved specifically for presbyopia in the United Kingdom. However, Yuvezzi is not alone in seeking that opportunity, with another United States-approved presbyopia drop already submitted to the same regulator.
Why does the MHRA recognition pathway shorten the route without guaranteeing approval?
Tenpoint Therapeutics filed the Yuvezzi application through the Medicines and Healthcare products Regulatory Agency’s International Recognition Procedure. The pathway allows the United Kingdom regulator to use assessments and approvals from recognised overseas regulators, including the United States Food and Drug Administration, while retaining responsibility for the final United Kingdom decision.
That distinction matters. The International Recognition Procedure is intended to reduce duplication, but it does not convert a United States approval into an automatic United Kingdom marketing authorisation. The Medicines and Healthcare products Regulatory Agency can still examine product quality, manufacturing, safety monitoring, labelling, risk management and any differences between the proposed United Kingdom product and the version reviewed in the United States.
The procedure offers two principal assessment timetables. Recognition A generally carries a 60-day timetable, while Recognition B follows a 110-day timetable and may include a formal pause for the applicant to respond to regulatory questions. Both periods begin only after the application has been validated. Tenpoint Therapeutics did not disclose which recognition timetable applies to Yuvezzi, meaning it would be premature to forecast a decision date.
The recent United States approval gives Tenpoint Therapeutics a relevant regulatory foundation. It also means that much of the clinical, nonclinical and manufacturing dossier has already undergone assessment by a major regulator. Nevertheless, the United Kingdom agency will determine whether the evidence and proposed product information satisfy domestic requirements.
A marketing authorisation, if eventually granted, would remove the principal regulatory barrier to commercialisation. It would not settle questions about pricing, distribution, prescriber adoption or the extent to which patients would pay for a pharmaceutical alternative to reading glasses.
What do the BRIO I and BRIO II results show about onset, duration and evidence strength?
The Yuvezzi application is supported by the BRIO I and BRIO II Phase 3 studies, both of which were randomised, double-masked and controlled. Their designs addressed different regulatory questions, with BRIO I examining whether the fixed combination offered a benefit over its individual active ingredients and BRIO II comparing Yuvezzi with a vehicle control while also generating longer-term safety data.
BRIO I was a crossover study in which 182 adults aged between 45 and 80 received single administrations of Yuvezzi, carbachol alone and brimonidine tartrate alone, with at least three days separating the treatments. This active-controlled design was important because a fixed-dose combination must demonstrate that combining the ingredients contributes something beyond administering either component by itself.
The principal efficacy assessment measured the proportion of participants who gained at least three lines, or 15 letters, in binocular uncorrected near visual acuity without losing at least one line of binocular uncorrected distance visual acuity. That combined endpoint was intended to test whether near vision improved without imposing a clinically relevant distance-vision penalty.
At one hour, 49.4% of Yuvezzi recipients met the endpoint, compared with 22.7% after brimonidine tartrate and 35% after carbachol. At two hours, the respective response rates were 51.1%, 26.7% and 39.8%. The combination also remained statistically superior to the two individual ingredients at four and six hours.
The picture was less differentiated at eight hours in BRIO I. At that time point, 13.5% of participants met the endpoint with Yuvezzi, compared with 12.5% for brimonidine tartrate and 8.6% for carbachol, with neither comparison reaching statistical significance. This does not negate the earlier benefit, but it shows why claims about duration need to distinguish pupil constriction from demonstrated superiority on the functional visual-acuity endpoint.
BRIO II randomised 436 participants to a single dose of Yuvezzi or vehicle, with 218 in each group. In that study, 38.2% of Yuvezzi-treated participants met the combined near and distance vision endpoint at one hour, compared with 3.7% in the vehicle group. At two hours, the rates were 34.1% and 3.7%, respectively.
A statistically significant difference remained at eight hours in BRIO II, when 10.2% of Yuvezzi recipients met the endpoint compared with 3.2% of vehicle recipients. The United States prescribing information therefore supports a measurable efficacy benefit through eight hours against vehicle, while the company separately reported that pupil constriction was observed for up to 10 hours.
BRIO II also incorporated six months of daily dosing followed by a six-month open-label extension. The United States label states that 358 participants received Yuvezzi during the long-term safety portion. This provides a more substantial duration of exposure than the short efficacy studies commonly associated with lifestyle-oriented ophthalmic treatments, although controlled effectiveness data from a single-dose assessment should not be confused with evidence that every patient will receive the same benefit throughout a full day.
Why does Yuvezzi’s dual-agent mechanism matter without reversing presbyopia itself?
Presbyopia develops as the natural lens of the eye becomes less flexible with age and progressively loses its ability to focus on nearby objects. Yuvezzi does not restore that lost lens flexibility or reverse the underlying ageing process. Its proposed mechanism instead uses pupil modulation to increase depth of focus and improve near visual acuity.
Carbachol is a cholinergic agent that constricts the iris sphincter and affects the ciliary body. Brimonidine tartrate is an alpha-adrenergic receptor agonist that reduces contraction of the iris dilator muscle. Together, the ingredients create a smaller pupil and a pinhole-like optical effect intended to sharpen near vision while preserving useful distance vision.
The combination is Tenpoint Therapeutics’ primary point of differentiation. Its regulatory programme was designed not merely to show that the formulation performed better than vehicle, but also that the two active ingredients contributed to the product’s effect.
For patients and prescribers, the practical appeal may be the possibility of once-daily near-vision support without surgery, contact lenses or repeatedly reaching for reading glasses. Yet reading glasses remain inexpensive, familiar and effective. Yuvezzi therefore has to compete on convenience, duration, tolerability and the value patients attach to reducing their dependence on corrective eyewear.
That makes the commercial test more subtle than the prevalence figures suggest. Presbyopia affects a vast adult population, but a large affected population is not equivalent to a readily obtainable prescription market. Many adults may continue using glasses, while pharmaceutical treatment may initially appeal most strongly to people seeking flexibility for work, social activities or situations in which eyewear is inconvenient.
What safety and tolerability questions could shape real-world use in the United Kingdom?
Tenpoint Therapeutics reported that no treatment-related serious adverse events were observed across more than 72,000 dosing days monitored in BRIO II. That long exposure period strengthens the safety package, particularly for a product intended for potentially repeated daily use, but it does not mean Yuvezzi is free from adverse effects or prescribing limitations.
According to the United States prescribing information, adverse reactions reported in more than 10% to 16% of participants included headache and eye irritation upon instillation. Eye pain upon instillation and visual impairment were reported in more than 5% to 7% of participants. Most reactions were described as mild or temporary, although real-world persistence will depend on whether users consider those effects acceptable relative to the convenience gained.
The United States label also warns that miotic eye drops can cause temporary blurred, dim or dark vision and advises caution with night driving or hazardous activities in poor illumination. Rare retinal tears and detachments have been reported with miotics as a class, with higher risk among people with pre-existing retinal disease. The label additionally identifies considerations involving iritis, vascular insufficiency and certain interacting medicines.
The eventual United Kingdom product information may not reproduce every aspect of the United States label in identical language. The Medicines and Healthcare products Regulatory Agency will determine the appropriate warnings, contraindications, monitoring and risk-management requirements for the United Kingdom market.
Tolerability could become a decisive competitive variable because presbyopia is not generally treated like an immediately threatening disease. Patients choosing an optional pharmaceutical approach may have a lower tolerance for discomfort, headache or temporary visual disturbance than patients taking medicine for a more serious condition. Convenient dosing gets people through the door, but continued use will depend on whether the lived experience matches the promise.
Can Yuvezzi win a first-mover advantage as Vizz enters the same United Kingdom race?
Tenpoint Therapeutics may be seeking to establish a new United Kingdom prescription category, but it is not the only company pursuing that position. LENZ Therapeutics, Inc. (Nasdaq: LENZ) submitted a United Kingdom marketing authorisation application for Vizz, its once-daily aceclidine ophthalmic solution, on April 20, 2026.
Vizz received United States Food and Drug Administration approval in July 2025 and is supported by the CLARITY Phase 3 programme. Yuvezzi, meanwhile, became the first United States-approved fixed-dose combination presbyopia eye drop in January 2026. The products therefore arrive with different pharmacological strategies and different claims to differentiation.
The earlier Vizz submission gives LENZ Therapeutics a chronological lead, but it does not establish which application will be decided first. Validation timing, recognition classification, regulatory questions and company response periods can all influence the sequence. It is also possible that the United Kingdom market could move from having no authorised prescription presbyopia drops to having more than one within a relatively short period.
Direct comparisons between the products would be unreliable without a head-to-head trial. Differences in study populations, visual-acuity measures, assessment times and trial designs prevent isolated response rates from establishing superiority. For clinicians, differentiation may ultimately depend on duration, consistency, pupil selectivity, safety, ease of administration and how individual patients respond.
Competition could also help create the market. Multiple companies educating eye care professionals and consumers may expand awareness more efficiently than a single entrant could. The less comfortable possibility for each developer is that the same activity could make presbyopia drops a crowded convenience category before prescribing habits have fully formed.
What will determine whether regulatory progress becomes a viable United Kingdom launch?
Tenpoint Therapeutics enters the United Kingdom process with advantages that many development-stage companies lack. Yuvezzi is already approved and commercially available in the United States, and the company secured a US$235 million financing package in January 2026 to support commercialisation. That package comprised an US$85 million Series B preferred-stock financing and a US$150 million senior secured term-loan facility, rather than US$235 million of equity capital already received without conditions.
The funding provides resources for manufacturing, commercial infrastructure and international regulatory work, although every new geography creates additional execution demands. A United Kingdom launch would require product supply, compliant packaging, pharmacovigilance, distribution, prescriber engagement and a pricing strategy that reflects the competitive reality of inexpensive reading glasses.
Tenpoint Therapeutics has not disclosed a United Kingdom launch partner, expected price or commercial timetable. Those details may remain premature while the application is under review, but they will become important if authorisation is granted. The company must also decide whether to build a direct commercial presence, use a local partner or adopt a more targeted specialist distribution model.
The next measurable event is not commercial launch but regulatory validation and confirmation of how the application will be assessed. Any subsequent questions from the Medicines and Healthcare products Regulatory Agency will provide a more meaningful indication of timing than the submission announcement alone.
Yuvezzi’s United States approval has removed one layer of clinical and regulatory uncertainty, and the International Recognition Procedure offers a credible route into Britain. The harder test begins after that: whether a once-daily dual-agent drop can persuade prescribers and adults with presbyopia that pharmacological convenience is worth paying for in a market where reading glasses are already doing a perfectly serviceable, if decidedly less glamorous, job.
